The short version of incretin receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
=== Certification of 2020 presidential election === On January 6, 2021, Wittman was one of the 147 Republican members of the U.S. Congress who objected to certifying the 2020 presidential election. He voted against certifying Pennsylvania's electors after a day of violence as the U.S. Capitol was breached by Trump supporters who disrupted proceedings, despite no clear evidence of widespread voter fraud.
=== Bulk manufacture === Quantum dot manufacturing relies on a process called high temperature dual injection which has been scaled by multiple companies for commercial applications that require large quantities (hundreds of kilograms to tons) of quantum dots. This reproducible production method can be applied to a wide range of quantum dot sizes and compositions. The bonding in certain cadmium-free quantum dots, such as III–V-based quantum dots, is more covalent than that in II–VI materials, therefore it is more difficult to separate nanoparticle nucleation and growth via a high temperature dual injection synthesis. An alternative method of quantum dot synthesis, the molecular seeding process, provides a reproducible route to the production of high-quality quantum dots in large volumes. The process utilises identical molecules of a molecular cluster compound as the nucleation sites for nanoparticle growth, thus avoiding the need for a high temperature injection step. Particle growth is maintained by the periodic addition of precursors at moderate temperatures until the desired particle size is reached. The molecular seeding process is not limited to the production of cadmium-free quantum dots; for example, the process can be used to synthesise kilogram batches of high-quality II–VI quantum dots in just a few hours. Another approach for the mass production of colloidal quantum dots can be seen in the transfer of the well-known hot-injection methodology for the synthesis to a technical continuous flow system.
On 23 July 1952, a law combined the GDR's municipal districts (Kreise) into 14 regional districts (Bezirke), and subsequently, on 25 July 1952, the state governments transferred their administrative tasks to the new regional districts. With this law, the Länder were in effect dissolved, and the GDR had become a highly centralized state. While they formally remained in existence, they no longer had any political or administrative functions. The Bezirke were drawn without regard to the borders of the Länder and each named after their capitals, from north to south: Rostock, Neubrandenburg, Schwerin, Potsdam, Frankfurt (Oder), Magdeburg, Cottbus, Halle, Leipzig, Erfurt, Dresden, Karl-Marx-Stadt (named Chemnitz until 1953), Gera and Suhl. The Länderkammer also remained in existence and its members were elected in 1954 by combined sessions of the Bezirkstage (district assemblies) in each Land and in 1958 directly by the Bezirkstage. However, on 8 December 1958, the Länderkammer formally dissolved itself with no objections being raised. The Länder continued to exist de jure up until the entry into force of the 1968 Constitution, which formalized their abolition. Due to its special status, East Berlin was originally not counted as a Bezirk. In 1961, after the construction of the Berlin Wall, East Berlin came to be recognised in GDR administration as a 15th district, though it retained a special status until the adoption of the 1968 Constitution formally designated it as Bezirk Berlin.
TrkC (pronounced "Track C"), is apparently the "physiologic" receptor, in that it binds with greatest affinity to NT-3. However, NT-3 is capable of binding and signaling through a TrkC-related receptors called TrkB. Finally, NT-3 also binds a second-receptor type besides Trk receptors, called the LNGFR (for "low affinity nerve growth factor receptor).
As with all opioids, the effects of fentanyl can be reversed with naloxone, or other opiate antagonists. Naloxone is increasingly available to the public. Illicitly synthesized fentanyl powder has also appeared on the United States market. Because of the extremely high strength of pure fentanyl powder, it is very difficult to dilute appropriately; often the resulting mixture may be far too strong and, therefore, very dangerous. Some heroin dealers mix fentanyl powder with heroin to increase potency or compensate for low-quality heroin. In 2006, illegally manufactured, non-pharmaceutical fentanyl, often mixed with cocaine or heroin, caused an outbreak of overdose deaths in the United States and Canada. Deaths were heavily concentrated in the cities of Dayton, Ohio; Chicago, Illinois; Detroit, Michigan; and Philadelphia, Pennsylvania.
Sources: en.wikipedia.org
CDMT has been used to activate alcohols, transforming them into electrophiles for a variety of transformations. It has been used in glycosylations. The anomeric position can be activated selectively without protecting the other hydroxy groups. The isolated CDMT-adduct undergoes stereoselective reaction with alcohols when used as solvent in the presence of catalytic [CuI(CH3CN)4]PF6. Isolated CDMT-adducts have also been used as electrophiles in nickel-catalyzed Suzuki-Miyaura cross couplings.
Many mammals communicate by vocalizing. Vocal communication serves many purposes, including in mating rituals, as warning calls, to indicate food sources, and for social purposes. Males often call during mating rituals to ward off other males and to attract females, as in the roaring of lions and red deer. The songs of the humpback whale may be signals to females; they have different dialects in different regions of the ocean. Social vocalizations include the territorial calls of gibbons, and the use of frequency in greater spear-nosed bats to distinguish between groups. The vervet monkey gives a distinct alarm call for each of at least four different predators, and the reactions of other monkeys vary according to the call. For example, if an alarm call signals a python, the monkeys climb into the trees, whereas the eagle alarm causes monkeys to seek a hiding place on the ground. Prairie dogs similarly have complex calls that signal the type, size, and speed of an approaching predator. Elephants communicate socially with a variety of sounds including snorting, screaming, trumpeting, roaring and rumbling. Some of the rumbling calls are infrasonic, below the hearing range of humans, and can be heard by other elephants up to 6 miles (9.7 km) away at still times near sunrise and sunset.
They called an ambulance which took him to Cedars-Sinai Medical Center, where Barker received stitches for an injured forehead and was released; he also hurt his left knee. Barker slipped and hit his head at home on June 19, 2017. His maid drove him to the emergency room, where Barker was checked and released. His representative said it was not as serious as his earlier fall. In October and November 2018, Barker was rushed to the hospital for severe back pain. Barker suffered another fall in January 2019, but he was not hospitalized. Barker's last public interview was with People in August 2021, in which he discussed The Price Is Right's upcoming 50th season on air. As of 2022, Burnet stated that, other than some non-prescription supplements such as collagen and a meal replacement drink to replenish nutrients not found naturally in Barker's vegetarian diet, he took only one prescription medication for hypothyroidism. On August 26, 2023, Barker died at his home in Los Angeles at the age of 99 of natural causes related to following several years fighting with Alzheimer's disease, a condition that Burnet and Barker's publicity team had kept hidden from the public. Hypertension, hyperlipidemia and hypothyroidism were listed as secondary causes of death. Barker was interred alongside his wife at Forest Lawn Memorial Park – Hollywood Hills.
She played the role of Amelia Slater in the Fox series Pitch, about Ginny Baker (Kylie Bunbury), a young black woman who makes history by becoming the first woman to play for a Major League Baseball team. The series ran for a season, which was released in 2016. From 2019 to 2020, Larter acted in the recurring role of Grace Sawyer in the police procedural series The Rookie on ABC In 2021, she played the lead role in the neo-western film The Last Victim. She starred in the thriller The Man in the White Van, which premiered at the 2023 Newport Beach Film Festival and was released in December 2024 to mixed reviews. In 2024, Larter co-starred in Taylor Sheridan’s show Landman, starring Billy Bob Thornton. Larter plays Angela Norris, a “cartoonish” funny caricature of a gold-digging ex-wife.
Sources: en.wikipedia.org
{\displaystyle {\ce {{^{232}_{90}Th}->[{\text{(n,}}\gamma {\text{)}}]{^{233}_{90}Th}->[\beta ^{-}][{\text{21.8 min}}]{^{233}_{91}Pa}->[\beta ^{-}][{\text{27 days}}]{^{233}_{92}U}\ (->[\alpha ][1.60\times 10^{5}{\text{years}}])}}}
== Toxicity == Buformin was withdrawn from the market in many countries due to an elevated risk of causing lactic acidosis (although not the US, where it was never sold). Buformin is still available and prescribed in Romania (timed release Silubin Retard is sold by Zentiva), Hungary, Taiwan and Japan (sold by Nichi-Iko Pharmaceutical Co., Ltd as "DIBETOS" tablets, each containing 50 mg buformin hydrochloride). The lactic acidosis occurred only in patients with a buformin plasma level of greater than 0.60 μg/mL and was rare in patients with normal renal function. In one report, the toxic oral dose was 329 ± 30 mg/day in 24 patients who developed lactic acidosis on buformin. Another group of 24 patients on 258 ± 25 mg/day did not develop lactic acidosis on buformin.
== Inhibitors == Several inhibitors of PLP enzymes are known. One type of inhibitor forms an electrophile with PLP, causing it to irreversibly react with the active site lysine. Acetylenic compounds (e.g. propargylglycine) and vinylic compounds (e.g. vinylglycine) are such inhibitors. A different type of inhibitor inactivates PLP, and such are α-methyl and amino-oxy substrate analogs (e.g. α-methylglutamate). Still other inhibitors have good leaving groups that nucleophilically attack the PLP. Such is chloroalanine, which inhibits a large number of enzymes. Examples of inhibitors:
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.